Profil
Piotr Michal Korycki currently works at Polpharma Biologics S.A., as President from 2021 and Comarch SA, as Chief Financial Officer & Vice President from 2025.
Mr. Korycki also formerly worked at TVN SA, as Chief Financial Officer & Vice President from 2003 to 2018.
Mr. Korycki received his graduate degree from Warsaw School of Economics.
Aktive Positionen von Piotr Michal Korycki
| Unternehmen | Position | Beginn |
|---|---|---|
| COMARCH SA | Finanzdirektor/CFO | 01.09.2025 |
Polpharma Biologics S.A.
Polpharma Biologics S.A. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals, biobetters and biosimilars | Präsident | 01.09.2021 |
Ehemalige bekannte Positionen von Piotr Michal Korycki
| Unternehmen | Position | Ende |
|---|---|---|
Pricewaterhousecoopers Securities SA
Pricewaterhousecoopers Securities SA Miscellaneous Commercial ServicesCommercial Services Provides assurance, tax and advisory services | Corporate Officer/Principal | - |
| TVN SA | Vorstandsvorsitzender | - |
Ausbildung von Piotr Michal Korycki
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Comarch SA
Comarch SA Information Technology ServicesTechnology Services Provides information technology solutions and services | Technology Services |
TVN SA
TVN SA BroadcastingConsumer Services Operates as a television broadcasting company | Consumer Services |
Warsaw School of Economics
Warsaw School of Economics Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pricewaterhousecoopers Securities SA
Pricewaterhousecoopers Securities SA Miscellaneous Commercial ServicesCommercial Services Provides assurance, tax and advisory services | Commercial Services |
Polpharma Biologics S.A.
Polpharma Biologics S.A. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals, biobetters and biosimilars | Health Technology |
















